July/August 2010, Vol 1, No 3

Direct-to-Consumer Genetics/Genomics: A “New Paradigm” in Providing Healthcare Information

Genomic Testing

July/August 2010, Vol 1, No 3

Clinical Trials: Understanding Cost, Coverage Implications

Clinical Trials

July/August 2010, Vol 1, No 3

How Will Costs Be Contained in the New Healthcare Environment?

Economics & Value

July/August 2010, Vol 1, No 3

Adherence to Colon Cancer Chemotherapy Guidelines Depends on Treatment Setting

Chemotherapy, Personalized Medicine

July/August 2010, Vol 1, No 3

Reasons for Breast Cancer Care Disparities Remain Unclear

Disparities in Oncology

July/August 2010, Vol 1, No 3

Comparative Effectiveness Research Will Help Guide Health Policy

Health Policy, Policies & Guidelines

July/August 2010, Vol 1, No 3

Pathway Compliance Reduces Drug, Nondrug Expenses

Pathways, Policies & Guidelines

July/August 2010, Vol 1, No 3

Evaluation of a regional payer-based pay-for-quality (P4Q)oncology program showed thatPathways programs can greatly reduce the cost of cancer care by slowingthe growth rate of both drug andnondrug expenses.

The New Face of the Community Oncology Practice

Community Oncology, Economics & Value

July/August 2010, Vol 1, No 3

Cost Considerations Change Dialogue

ASCO Annual Meeting, ASCO

July/August 2010, Vol 1, No 3

Although financial concerns are increasingly influencing choices in cancer therapy, barriers to cost discussions between physicians and patients often limit the scope of such discussions.

Do End-of-Life Products Deserve Special Treatment?

End-of-Life Care, ISPOR Annual Meeting, Policies & Guidelines

July/August 2010, Vol 1, No 3

Page 1 of 2

1
2